Meta AnalysisID 2522
多奈哌齐、加兰他敏、卡巴拉汀、美金刚和甘露特钠治疗阿尔茨海默病的有效性和安全性：一项系统评价与Meta分析
CRD42022360642
Is there any difference in safety and effectiveness between anti-dementia drugs and placebo in the treatment of mild to moderate Alzheimer's disease?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2522
- Evidence Id
- 11080
- Core Evidence Id
- 11080
- Source Meta Analysis Id
- 2471
- Herb2 Meta Analysis Id
- HBMA002471
- Crd Id
- CRD42022360642
- Title
- Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate for the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis
- Review Question
- Is there any difference in safety and effectiveness between anti-dementia drugs and placebo in the treatment of mild to moderate Alzheimer's disease?
- Study Type Included
- Inclusion: (1) double-blind, parallel-group, placebo-controlled, with random assignment to Donepezil, Galantamine, Rivastigmine, Memantine or sodium oligomannate; (2) full-text articles were written by English; (3) participants in the studies were mild to moderate AD; (4) Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannatewas compared with placebo directly in trials; (5) participants in the studies were generally over 50 years old Exclusion: (1) participants are not patients with Alzheimer's disease; (2) the drug in studies was not Donepezil, Galantamine, Rivastigmine, Memantine or sodium oligomannate; (3)Non-double-blind, non-randomized, no placebo.
- Condition Being Studied
- Alzheimer’s disease(AD) is the most common cause of dementia, affecting more than 36 million people worldwide. It has been predicted that by 2050, this figure will more than 115 million.This age-associated neurodegenerative disorder has an insidious onset with progressive deterioration in cognition, functional ability, behavior, and mood. Regarding patients with mild-to-moderate AD, the American Psychiatric Association recommends second generation ChEIs, donepezil, galantamine and rivastigmine for mild-to-moderate AD.Memantine and sodium oligomannate were gradually added to the treatment in recent years, but controversy over these drugs still be continued.
- Participant
- Inclusion: (1) participants in the studies were mild-to-moderate AD; (2) Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate were compared with placebo directly in trials; (3) participants in the studies were generally over 50 years old Exclusion: (1) participants are not patients with Alzheimer's disease; (2) the drug in studies was not Donepezil, Galantamine, Rivastigmine, Memantine or sodium oligomannate
- Animal
- Human Disease Modelled
- Intervention
- Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate
- Comparator Control
- Placebo
- Main Outcome
- We focus on the Alzheimer’s Disease Assessment Scale (ADAS-cog), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS/ADL), Neuropsychiatric Inventory (NPI), and the Clinician’s Interview Based Assessment of Change-Plus (CIBIC plus) as the primary measure of cognition, function, behavior, and global assessment of change, respectively.
- Outcome Measure
- Additional Outcome
- we recorded the incidence of adverse events (AEs) and serious adverse events (SAEs) as the second outcome to assess the safety of the different drug doses.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Rivastigmine; Sodium
- Contact
- yan chen [email protected]
- Organisational Affiliation
- Zhejiang Chinese Medical University
- Funding Source
- Research and development of key technologies and core equipment for early screening and diagnosis of AD, Ministry of Science and Technology of the People's Republic of China（2022YFE0199300）
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-09-16
- Registration Date
- 2022-09-27
- Anticipated Start Date
- 2022-08-09
- Anticipated Completion Date
- 2022-11-09
- Title Cn
- 多奈哌齐、加兰他敏、卡巴拉汀、美金刚和甘露特钠治疗阿尔茨海默病的有效性和安全性：一项系统评价与Meta分析
- Title En
- Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate for the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete